依田 成玄

最終更新日時: 2019/06/22 12:26:32

印刷する

氏名(漢字/フリガナ/アルファベット表記)
依田 成玄/ヨダ アキノリ/Yoda, Akinori
所属部署・職名(部局/所属/講座等/職名)
医学研究科/次世代腫瘍分子創薬講座(産学共同)/特定准教授
取得学位
学位名(日本語) 学位名(英語) 大学(日本語) 大学(英語) 取得区分
修士(理学) M.S. 東京大学 Tokyo University
博士(医学) Ph.D. 大阪大学 Osaka University
プロフィール
(日本語)
がんの研究、特に新規がん遺伝子の発がんにおける機能解析及びこの分子を標的とした新規抗がん剤の開発を行っている。
(英語)
I am doing cancer research: functional analysis of novel oncogenes and development of novel cancer drugs targeting the oncogenes.
使用言語
言語名(japanese) 言語名(english) コード
英語
ORCID ID
https://orcid.org/0000-0002-7806-1909
researchmap URL
https://researchmap.jp/read0054674
研究テーマ
(日本語)
白血病の新規治療標的分子の研究
(英語)
Novel therapeutic targets for leukemia
研究概要
(日本語)
創薬ベンチャーと共同で、新規の抗がん剤及び新規のがん免疫療法薬の開発を行っている。このプロジェクトでは、患者検体(主に白血病・リンパ腫)やマウスin vivoモデル(ノックアウト・ノックアウトイン、患者腫瘍組織移植PDXモデル、PD-1抗体治療モデル)のオミックス解析(DNA/RNAシークエンシング、プロテオミクス解析)を利用した創薬研究を行っている。
(英語)
I am doing a research of drug development for cancer collaborating with biotech companies. In this project we employ the latest technologies including mouse in vivo models (knock-in/knock-out mice, patient-derived Xenograft (PDX) models and syngeneic mouse models for cancer immunotherapy) and OMICs analyses (DNA/RNA sequencing and proteomics analysis).
研究分野(キーワード)
キーワード(日本語) キーワード(英語)
血液腫瘍学 Hematology/Oncology
がんと遺伝子 Oncogene
ゲノム解析 Genomic analysis
疾患モデル Disease model
論文
著者 著者(日本語) 著者(英語) タイトル タイトル(日本語) タイトル(英語) 書誌情報等 書誌情報等(日本語) 書誌情報等(英語) 出版年月 査読の有無 記述言語 掲載種別 公開
Kotani S, Yoda A, Kon A, Kataoka K, Ochi Y, Shiozawa Y, Hirsch C, Takeda J, Ueno H, Yoshizato T, Yoshida K, Nakagawa MM, Nannya Y, Kakiuchi N, Yamauchi T, Aoki K, Shiraishi Y, Miyano S, Maeda T, Maciejewski JP, Takaori-Kondo A, Ogawa S, Makishima H Kotani S, Yoda A, Kon A, Kataoka K, Ochi Y, Shiozawa Y, Hirsch C, Takeda J, Ueno H, Yoshizato T, Yoshida K, Nakagawa MM, Nannya Y, Kakiuchi N, Yamauchi T, Aoki K, Shiraishi Y, Miyano S, Maeda T, Maciejewski JP, Takaori-Kondo A, Ogawa S, Makishima H Kotani S, Yoda A, Kon A, Kataoka K, Ochi Y, Shiozawa Y, Hirsch C, Takeda J, Ueno H, Yoshizato T, Yoshida K, Nakagawa MM, Nannya Y, Kakiuchi N, Yamauchi T, Aoki K, Shiraishi Y, Miyano S, Maeda T, Maciejewski JP, Takaori-Kondo A, Ogawa S, Makishima H Molecular pathogenesis of disease progression in MLL-rearranged AML. Molecular pathogenesis of disease progression in MLL-rearranged AML. Molecular pathogenesis of disease progression in MLL-rearranged AML. Leukemia Leukemia Leukemia 2018/09 公開
Joyce CE, Yanez AG, Mori A, Yoda A, Carroll JS, Novina CD Joyce CE, Yanez AG, Mori A, Yoda A, Carroll JS, Novina CD Joyce CE, Yanez AG, Mori A, Yoda A, Carroll JS, Novina CD Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E. Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E. Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E. Cancer research, 77, 3, 613-622 Cancer research, 77, 3, 613-622 Cancer research, 77, 3, 613-622 2017/02 公開
Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Hess JM, Gimelbrant AA, Beroukhim R, Lawrence MS, Getz G, Lane AA Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Hess JM, Gimelbrant AA, Beroukhim R, Lawrence MS, Getz G, Lane AA Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Hess JM, Gimelbrant AA, Beroukhim R, Lawrence MS, Getz G, Lane AA Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nature genetics, 49, 1, 10-16 Nature genetics, 49, 1, 10-16 Nature genetics, 49, 1, 10-16 2017/01 公開
Grants JM, Ying LT, Yoda A, You CC, Okano H, Sawa H, Taubert S Grants JM, Ying LT, Yoda A, You CC, Okano H, Sawa H, Taubert S Grants JM, Ying LT, Yoda A, You CC, Okano H, Sawa H, Taubert S The Mediator Kinase Module Restrains Epidermal Growth Factor Receptor Signaling and Represses Vulval Cell Fate Specification in Caenorhabditis elegans. The Mediator Kinase Module Restrains Epidermal Growth Factor Receptor Signaling and Represses Vulval Cell Fate Specification in Caenorhabditis elegans. The Mediator Kinase Module Restrains Epidermal Growth Factor Receptor Signaling and Represses Vulval Cell Fate Specification in Caenorhabditis elegans. Genetics, 202, 2, 583-599 Genetics, 202, 2, 583-599 Genetics, 202, 2, 583-599 2016/02 公開
Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dölemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dölemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dölemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer cell, 28, 1, 29-41 Cancer cell, 28, 1, 29-41 Cancer cell, 28, 1, 29-41 2015/07 公開
Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nature medicine, 21, 1, 71-75 Nature medicine, 21, 1, 71-75 Nature medicine, 21, 1, 71-75 2015/01 公開
Mansour MR, Reed C, Eisenberg AR, Tseng JC, Twizere JC, Daakour S, Yoda A, Rodig SJ, Tal N, Shochat C, Berezovskaya A, DeAngelo DJ, Sallan SE, Weinstock DM, Izraeli S, Kung AL, Kentsis A, Look AT Mansour MR, Reed C, Eisenberg AR, Tseng JC, Twizere JC, Daakour S, Yoda A, Rodig SJ, Tal N, Shochat C, Berezovskaya A, DeAngelo DJ, Sallan SE, Weinstock DM, Izraeli S, Kung AL, Kentsis A, Look AT Mansour MR, Reed C, Eisenberg AR, Tseng JC, Twizere JC, Daakour S, Yoda A, Rodig SJ, Tal N, Shochat C, Berezovskaya A, DeAngelo DJ, Sallan SE, Weinstock DM, Izraeli S, Kung AL, Kentsis A, Look AT Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. British journal of haematology, 168, 2, 230-238 British journal of haematology, 168, 2, 230-238 British journal of haematology, 168, 2, 230-238 2015/01 公開
Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris MH, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris MH, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris MH, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature genetics, 46, 6, 618-623 Nature genetics, 46, 6, 618-623 Nature genetics, 46, 6, 618-623 2014/06 公開
Zhong J, Sharma J, Raju R, Palapetta SM, Prasad TS, Huang TC, Yoda A, Tyner JW, van Bodegom D, Weinstock DM, Ziegler SF, Pandey A Zhong J, Sharma J, Raju R, Palapetta SM, Prasad TS, Huang TC, Yoda A, Tyner JW, van Bodegom D, Weinstock DM, Ziegler SF, Pandey A Zhong J, Sharma J, Raju R, Palapetta SM, Prasad TS, Huang TC, Yoda A, Tyner JW, van Bodegom D, Weinstock DM, Ziegler SF, Pandey A TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. Database : the journal of biological databases and curation, 2014, bau007 Database : the journal of biological databases and curation, 2014, bau007 Database : the journal of biological databases and curation, 2014, bau007 2014 公開
van Bodegom D, Zhong J, Kopp N, Dutta C, Kim MS, Bird L, Weigert O, Tyner J, Pandey A, Yoda A, Weinstock DM van Bodegom D, Zhong J, Kopp N, Dutta C, Kim MS, Bird L, Weigert O, Tyner J, Pandey A, Yoda A, Weinstock DM van Bodegom D, Zhong J, Kopp N, Dutta C, Kim MS, Bird L, Weigert O, Tyner J, Pandey A, Yoda A, Weinstock DM Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Blood, 120, 14, 2853-2863 Blood, 120, 14, 2853-2863 Blood, 120, 14, 2853-2863 2012/10 公開
Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM BCL2 suppresses PARP1 function and nonapoptotic cell death. BCL2 suppresses PARP1 function and nonapoptotic cell death. BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer research, 72, 16, 4193-4203 Cancer research, 72, 16, 4193-4203 Cancer research, 72, 16, 4193-4203 2012/08 公開
Zhong J, Kim MS, Chaerkady R, Wu X, Huang TC, Getnet D, Mitchell CJ, Palapetta SM, Sharma J, O'Meally RN, Cole RN, Yoda A, Moritz A, Loriaux MM, Rush J, Weinstock DM, Tyner JW, Pandey A Zhong J, Kim MS, Chaerkady R, Wu X, Huang TC, Getnet D, Mitchell CJ, Palapetta SM, Sharma J, O'Meally RN, Cole RN, Yoda A, Moritz A, Loriaux MM, Rush J, Weinstock DM, Tyner JW, Pandey A Zhong J, Kim MS, Chaerkady R, Wu X, Huang TC, Getnet D, Mitchell CJ, Palapetta SM, Sharma J, O'Meally RN, Cole RN, Yoda A, Moritz A, Loriaux MM, Rush J, Weinstock DM, Tyner JW, Pandey A TSLP signaling network revealed by SILAC-based phosphoproteomics. TSLP signaling network revealed by SILAC-based phosphoproteomics. TSLP signaling network revealed by SILAC-based phosphoproteomics. Molecular & cellular proteomics : MCP, 11, 6, M112.017764 Molecular & cellular proteomics : MCP, 11, 6, M112.017764 Molecular & cellular proteomics : MCP, 11, 6, M112.017764 2012/06 公開
Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. The Journal of experimental medicine, 209, 2, 259-273 The Journal of experimental medicine, 209, 2, 259-273 The Journal of experimental medicine, 209, 2, 259-273 2012/02 公開
Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer discovery, 2, 1, 47-55 Cancer discovery, 2, 1, 47-55 Cancer discovery, 2, 1, 47-55 2012/01 公開
Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM Next-generation cDNA screening for oncogene and resistance phenotypes. Next-generation cDNA screening for oncogene and resistance phenotypes. Next-generation cDNA screening for oncogene and resistance phenotypes. PloS one, 7, 11, e49201 PloS one, 7, 11, e49201 PloS one, 7, 11, e49201 2012 公開
Tsai AG, Yoda A, Weinstock DM, Lieber MR Tsai AG, Yoda A, Weinstock DM, Lieber MR Tsai AG, Yoda A, Weinstock DM, Lieber MR t(X;14)(p22;q32)/t(Y;14)(p11;q32) CRLF2-IGH translocations from human B-lineage ALLs involve CpG-type breaks at CRLF2, but CRLF2/P2RY8 intrachromosomal deletions do not. t(X;14)(p22;q32)/t(Y;14)(p11;q32) CRLF2-IGH translocations from human B-lineage ALLs involve CpG-type breaks at CRLF2, but CRLF2/P2RY8 intrachromosomal deletions do not. t(X;14)(p22;q32)/t(Y;14)(p11;q32) CRLF2-IGH translocations from human B-lineage ALLs involve CpG-type breaks at CRLF2, but CRLF2/P2RY8 intrachromosomal deletions do not. Blood, 116, 11, 1993-1994 Blood, 116, 11, 1993-1994 Blood, 116, 11, 1993-1994 2010/09 公開
Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, te Kronnie G, Bourquin JP, Domany E, Izraeli S Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, te Kronnie G, Bourquin JP, Domany E, Izraeli S Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, te Kronnie G, Bourquin JP, Domany E, Izraeli S Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 115, 5, 1006-1017 Blood, 115, 5, 1006-1017 Blood, 115, 5, 1006-1017 2010/02 公開
Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 107, 1, 252-257 Proceedings of the National Academy of Sciences of the United States of America, 107, 1, 252-257 Proceedings of the National Academy of Sciences of the United States of America, 107, 1, 252-257 2010/01 公開
Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, Tsukuda Y, Tsukada J, Kondo T, Tanaka Y, Minami Y Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, Tsukuda Y, Tsukada J, Kondo T, Tanaka Y, Minami Y Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, Tsukuda Y, Tsukada J, Kondo T, Tanaka Y, Minami Y Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. The Journal of biological chemistry, 283, 27, 18969-18979 The Journal of biological chemistry, 283, 27, 18969-18979 The Journal of biological chemistry, 283, 27, 18969-18979 2008/07 公開
Yoo SK, Onishi N, Kato N, Yoda A, Minami Y Yoo SK, Onishi N, Kato N, Yoda A, Minami Y Yoo SK, Onishi N, Kato N, Yoda A, Minami Y [Relationship between abnormalities of genes involved in DNA damage responses and malignant tumors/autoimmune diseases]. [Relationship between abnormalities of genes involved in DNA damage responses and malignant tumors/autoimmune diseases]. [Relationship between abnormalities of genes involved in DNA damage responses and malignant tumors/autoimmune diseases]. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 29, 3, 136-147 Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 29, 3, 136-147 Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 29, 3, 136-147 2006/06 公開
Wirschell M, Pazour G, Yoda A, Hirono M, Kamiya R, Witman GB Wirschell M, Pazour G, Yoda A, Hirono M, Kamiya R, Witman GB Wirschell M, Pazour G, Yoda A, Hirono M, Kamiya R, Witman GB Oda5p, a novel axonemal protein required for assembly of the outer dynein arm and an associated adenylate kinase. Oda5p, a novel axonemal protein required for assembly of the outer dynein arm and an associated adenylate kinase. Oda5p, a novel axonemal protein required for assembly of the outer dynein arm and an associated adenylate kinase. Molecular biology of the cell, 15, 6, 2729-2741 Molecular biology of the cell, 15, 6, 2729-2741 Molecular biology of the cell, 15, 6, 2729-2741 2004/06 公開

  • <<
  • >>
  • 表示
タイトル言語:
Misc
著者 著者(日本語) 著者(英語) タイトル タイトル(日本語) タイトル(英語) 書誌情報等 書誌情報等(日本語) 書誌情報等(英語) 出版年月 査読の有無 記述言語 掲載種別 公開
Chk2 kinase is required for methylglyoxal-induced G2/M cell-cycle checkpoint arrest: implication of cell-cycle checkpoint regulation in diabetic oxidative stress signaling Chk2 kinase is required for methylglyoxal-induced G2/M cell-cycle checkpoint arrest: implication of cell-cycle checkpoint regulation in diabetic oxidative stress signaling Chk2 kinase is required for methylglyoxal-induced G2/M cell-cycle checkpoint arrest: implication of cell-cycle checkpoint regulation in diabetic oxidative stress signaling Genes To Cells, Vol. 12, No. 8, pp. 919-28 Genes To Cells, Vol. 12, No. 8, pp. 919-28 Genes To Cells, Vol. 12, No. 8, pp. 919-28 2007 公開
DNA損傷時におけるChk1/Chk2によるWip1のリン酸化および安定化制御(Chk1/Chk2 phosphorylates and stabilizes Wip1 in response to DNA damage)(英語) DNA損傷時におけるChk1/Chk2によるWip1のリン酸化および安定化制御(Chk1/Chk2 phosphorylates and stabilizes Wip1 in response to DNA damage)(英語) DNA損傷時におけるChk1/Chk2によるWip1のリン酸化および安定化制御(Chk1/Chk2 phosphorylates and stabilizes Wip1 in response to DNA damage)(英語) 日本癌学会総会記事, -巻, 66回, pp. 487-487 日本癌学会総会記事, -巻, 66回, pp. 487-487 日本癌学会総会記事, -巻, 66回, pp. 487-487 2007 公開
Genetically Engineered Mice Handbook / Mouse Models for Developmental Biology: Functional Analysis for Ror and Wnt Signaling Genetically Engineered Mice Handbook / Mouse Models for Developmental Biology: Functional Analysis for Ror and Wnt Signaling Genetically Engineered Mice Handbook / Mouse Models for Developmental Biology: Functional Analysis for Ror and Wnt Signaling Taylor & Francis Taylor & Francis Taylor & Francis 2006 公開
Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase Cell Death And Differentiation, Vol. 13, No. 7, pp. 1170-1180 Cell Death And Differentiation, Vol. 13, No. 7, pp. 1170-1180 Cell Death And Differentiation, Vol. 13, No. 7, pp. 1170-1180 2006 公開
【分子メカニズムから解き明かす疾患のサイエンス】 癌 DNA損傷応答システムとその破綻による癌化 【分子メカニズムから解き明かす疾患のサイエンス】 癌 DNA損傷応答システムとその破綻による癌化 【分子メカニズムから解き明かす疾患のサイエンス】 癌 DNA損傷応答システムとその破綻による癌化 実験医学, 24巻, 10号, pp. 1408-1415 実験医学, 24巻, 10号, pp. 1408-1415 実験医学, 24巻, 10号, pp. 1408-1415 2006 公開
Chk2キナーゼとWip1ホスファターゼの構造機能連関(Structure/function relationships in Chk2 kinase and Wip1 phosphatase)(英語) Chk2キナーゼとWip1ホスファターゼの構造機能連関(Structure/function relationships in Chk2 kinase and Wip1 phosphatase)(英語) Chk2キナーゼとWip1ホスファターゼの構造機能連関(Structure/function relationships in Chk2 kinase and Wip1 phosphatase)(英語) 日本癌学会65回総会記事, pp. 164-164 日本癌学会65回総会記事, pp. 164-164 日本癌学会65回総会記事, pp. 164-164 2006 公開
Wip1ホスファターゼによるATMキナーゼを介したDNA損傷応答シグナルの抑制機構 Wip1ホスファターゼによるATMキナーゼを介したDNA損傷応答シグナルの抑制機構 Wip1ホスファターゼによるATMキナーゼを介したDNA損傷応答シグナルの抑制機構 日本癌学会65回総会記事, pp. 164-165 日本癌学会65回総会記事, pp. 164-165 日本癌学会65回総会記事, pp. 164-165 2006 公開
Chk2キナーゼとWip1ホスファターゼの構造機能連関(Structure/function relationships in Chk2 kinase and Wip1 phosphatase)(英語) Chk2キナーゼとWip1ホスファターゼの構造機能連関(Structure/function relationships in Chk2 kinase and Wip1 phosphatase)(英語) Chk2キナーゼとWip1ホスファターゼの構造機能連関(Structure/function relationships in Chk2 kinase and Wip1 phosphatase)(英語) 日本癌学会総会記事, 巻, 65回, pp. 164-164 日本癌学会総会記事, 巻, 65回, pp. 164-164 日本癌学会総会記事, 巻, 65回, pp. 164-164 2006 公開
DNA損傷応答関連遺伝子の異常と悪性腫瘍・自己免疫疾患との関連について DNA損傷応答関連遺伝子の異常と悪性腫瘍・自己免疫疾患との関連について DNA損傷応答関連遺伝子の異常と悪性腫瘍・自己免疫疾患との関連について 日本臨床免疫学会会誌, 29巻, 3号, pp. 136-147 日本臨床免疫学会会誌, 29巻, 3号, pp. 136-147 日本臨床免疫学会会誌, 29巻, 3号, pp. 136-147 2006 公開
Structure-function analyses of Chk2 kinase and Wip1 phosphatase Structure-function analyses of Chk2 kinase and Wip1 phosphatase Structure-function analyses of Chk2 kinase and Wip1 phosphatase 2006 公開
Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1 Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1 Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1 2006 公開
Wip1 phosphatase is a negative regulator for ATM-mediated DNA damage response Wip1 phosphatase is a negative regulator for ATM-mediated DNA damage response Wip1 phosphatase is a negative regulator for ATM-mediated DNA damage response 2006 公開
Chk2キナーゼとWip1ホスファターゼの構造機能連関 Chk2キナーゼとWip1ホスファターゼの構造機能連関 Chk2キナーゼとWip1ホスファターゼの構造機能連関 2006 公開
Wip1ホスファターゼによるATMキナーゼを介したDNA損傷応答シグナルの抑制機構 Wip1ホスファターゼによるATMキナーゼを介したDNA損傷応答シグナルの抑制機構 Wip1ホスファターゼによるATMキナーゼを介したDNA損傷応答シグナルの抑制機構 2006 公開
Components of the transcriptional Mediator complex are required for asymmetric cell division in C. elegans Components of the transcriptional Mediator complex are required for asymmetric cell division in C. elegans Components of the transcriptional Mediator complex are required for asymmetric cell division in C. elegans Development (Cambridge, England), Vol. 132, No. 8, pp. 1885-1893 Development (Cambridge, England), Vol. 132, No. 8, pp. 1885-1893 Development (Cambridge, England), Vol. 132, No. 8, pp. 1885-1893 2005 公開
細胞周期チェックポイントのオン・オフ機構 細胞周期チェックポイントのオン・オフ機構 細胞周期チェックポイントのオン・オフ機構 放射線生物研究, 40巻, 2号, pp.67-81 放射線生物研究, 40巻, 2号, pp.67-81 放射線生物研究, 40巻, 2号, pp.67-81 2005 公開
DNA損傷とアポトーシス研究のがん治療への応用 DNA損傷に伴う細胞周期チェックポイントの作動・解除及びアポトーシスの制御機構とがんの分子標的治療への応用 DNA損傷とアポトーシス研究のがん治療への応用 DNA損傷に伴う細胞周期チェックポイントの作動・解除及びアポトーシスの制御機構とがんの分子標的治療への応用 DNA損傷とアポトーシス研究のがん治療への応用 DNA損傷に伴う細胞周期チェックポイントの作動・解除及びアポトーシスの制御機構とがんの分子標的治療への応用 日本癌学会64回総会記事, pp.29-30 日本癌学会64回総会記事, pp.29-30 日本癌学会64回総会記事, pp.29-30 2005 公開
Structure-function analyses of Chk2 kinase and Wip1 phosphatase Structure-function analyses of Chk2 kinase and Wip1 phosphatase Structure-function analyses of Chk2 kinase and Wip1 phosphatase 2005 公開
Wip1 phosphatase interacts with SQ/TQ domain of Chk2 kinase and dephosphorylates threonine68 through N-terminal region of Wip1 Wip1 phosphatase interacts with SQ/TQ domain of Chk2 kinase and dephosphorylates threonine68 through N-terminal region of Wip1 Wip1 phosphatase interacts with SQ/TQ domain of Chk2 kinase and dephosphorylates threonine68 through N-terminal region of Wip1 2005 公開
DNA損傷応答における核内Chk2キナーゼ・Wip1ホスファターゼの構造・機能連関解析 DNA損傷応答における核内Chk2キナーゼ・Wip1ホスファターゼの構造・機能連関解析 DNA損傷応答における核内Chk2キナーゼ・Wip1ホスファターゼの構造・機能連関解析 2005 公開
受容体型チロシンキナーゼRor2の細胞外・細胞内ドメイン依存的機能によるWntシグナルおよび細胞骨格系の制御 受容体型チロシンキナーゼRor2の細胞外・細胞内ドメイン依存的機能によるWntシグナルおよび細胞骨格系の制御 受容体型チロシンキナーゼRor2の細胞外・細胞内ドメイン依存的機能によるWntシグナルおよび細胞骨格系の制御 2005 公開
Ror2-mediated cytoskeletal reorganization by differential regulation of Dishevelled proteins Ror2-mediated cytoskeletal reorganization by differential regulation of Dishevelled proteins Ror2-mediated cytoskeletal reorganization by differential regulation of Dishevelled proteins 2005 公開
DNA損傷に伴う細胞周期チェックポイントの作動・解除及びアポトーシスの制御機構とがんの分子標的治療への応用 DNA損傷に伴う細胞周期チェックポイントの作動・解除及びアポトーシスの制御機構とがんの分子標的治療への応用 DNA損傷に伴う細胞周期チェックポイントの作動・解除及びアポトーシスの制御機構とがんの分子標的治療への応用 2005 公開
DNA損傷応答におけるWip1による細胞周期チェックポイントの解除機構 DNA損傷応答におけるWip1による細胞周期チェックポイントの解除機構 DNA損傷応答におけるWip1による細胞周期チェックポイントの解除機構 Cancer Science, 95巻, Suppl., pp. 440-440 Cancer Science, 95巻, Suppl., pp. 440-440 Cancer Science, 95巻, Suppl., pp. 440-440 2004 公開
Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines Cell Death And Differentiation, Vol. 11 Suppl 2, No. , pp. S153-S161 Cell Death And Differentiation, Vol. 11 Suppl 2, No. , pp. S153-S161 Cell Death And Differentiation, Vol. 11 Suppl 2, No. , pp. S153-S161 2004 公開
Oda5p, a novel axonemal protein required for assembly of the outer Dynein arm and an associated adenylate kinase Oda5p, a novel axonemal protein required for assembly of the outer Dynein arm and an associated adenylate kinase Oda5p, a novel axonemal protein required for assembly of the outer Dynein arm and an associated adenylate kinase Molecular Biology Of The Cell, Vol. 15, No. 6, pp. 2729-2741 Molecular Biology Of The Cell, Vol. 15, No. 6, pp. 2729-2741 Molecular Biology Of The Cell, Vol. 15, No. 6, pp. 2729-2741 2004 公開
The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase Iepsilon The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase Iepsilon The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase Iepsilon The Journal Of Biological Chemistry, Vol. 279, No. 48, pp. 50102-50109 The Journal Of Biological Chemistry, Vol. 279, No. 48, pp. 50102-50109 The Journal Of Biological Chemistry, Vol. 279, No. 48, pp. 50102-50109 2004 公開
DNA損傷応答におけるチェックポイントとDNA修復のクロストーク機構の解析 DNA損傷応答におけるチェックポイントとDNA修復のクロストーク機構の解析 DNA損傷応答におけるチェックポイントとDNA修復のクロストーク機構の解析 放射線生物研究, 39巻, 3号, pp. 244-257 放射線生物研究, 39巻, 3号, pp. 244-257 放射線生物研究, 39巻, 3号, pp. 244-257 2004 公開
放射線によるDNA損傷に伴う細胞周期チェックポイントのオン・オフ機構 放射線によるDNA損傷に伴う細胞周期チェックポイントのオン・オフ機構 放射線によるDNA損傷に伴う細胞周期チェックポイントのオン・オフ機構 日本放射線影響学会大会講演要旨集, 巻, 47回, pp. 54-54 日本放射線影響学会大会講演要旨集, 巻, 47回, pp. 54-54 日本放射線影響学会大会講演要旨集, 巻, 47回, pp. 54-54 2004 公開
WntとRor2によるPCP経路の制御 WntとRor2によるPCP経路の制御 WntとRor2によるPCP経路の制御 細胞工学, 23巻, 6, pp. 642-646 細胞工学, 23巻, 6, pp. 642-646 細胞工学, 23巻, 6, pp. 642-646 2004 公開
放射線によるDNA損傷に伴う細胞周期チェックポイントのオン・オフ機構 放射線によるDNA損傷に伴う細胞周期チェックポイントのオン・オフ機構 放射線によるDNA損傷に伴う細胞周期チェックポイントのオン・オフ機構 2004 公開
形態形成のシグナル伝達における受容体型チロシンキナーゼRor2とFGFR3の機能連関解析 形態形成のシグナル伝達における受容体型チロシンキナーゼRor2とFGFR3の機能連関解析 形態形成のシグナル伝達における受容体型チロシンキナーゼRor2とFGFR3の機能連関解析 2004 公開
Structure-function analyses of protein kinase and phosphatase involved in intranuclear signaling in response to DNA damage Structure-function analyses of protein kinase and phosphatase involved in intranuclear signaling in response to DNA damage Structure-function analyses of protein kinase and phosphatase involved in intranuclear signaling in response to DNA damage 2004 公開
The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase I epsilon The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase I epsilon The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase I epsilon 2004 公開
The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase Ⅰε The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase Ⅰε The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase Ⅰε 2004 公開
DNA損傷応答におけるWip1を介した細胞周期チェックポイントの解除機構 DNA損傷応答におけるWip1を介した細胞周期チェックポイントの解除機構 DNA損傷応答におけるWip1を介した細胞周期チェックポイントの解除機構 2004 公開
CKIeによる受容体型チロシンキナーゼRor2の活性化機構 CKIeによる受容体型チロシンキナーゼRor2の活性化機構 CKIeによる受容体型チロシンキナーゼRor2の活性化機構 2003 公開
CKIεによる受容体型チロシンキナーゼRor2の活性化機構 CKIεによる受容体型チロシンキナーゼRor2の活性化機構 CKIεによる受容体型チロシンキナーゼRor2の活性化機構 2003 公開
DNA損傷応答における核内シグナル伝達に関わる蛋白質キナーゼ・ホスファターゼの構造・機能連関解析 DNA損傷応答における核内シグナル伝達に関わる蛋白質キナーゼ・ホスファターゼの構造・機能連関解析 DNA損傷応答における核内シグナル伝達に関わる蛋白質キナーゼ・ホスファターゼの構造・機能連関解析 2003 公開
Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans Journal Of Receptor And Signal Transduction Research, Vol. 23, No. 1, pp. 1-15 Journal Of Receptor And Signal Transduction Research, Vol. 23, No. 1, pp. 1-15 Journal Of Receptor And Signal Transduction Research, Vol. 23, No. 1, pp. 1-15 2002 公開

  • <<
  • >>
  • 表示
タイトル言語: